TOKYO, May 14 (Pulse News Wire) – Kringle Pharma,inc. (4884.T) reported a net loss of ¥512 million for the quarter ending September 2026, compared to ¥512 million in the same period last year.
Revenue increased to ¥332 million from ¥35 million due to higher sales to Claris Corp. Research and development expenses rose to ¥973 million from ¥375 million, primarily driven by additional costs related to spinal injury drug development and preparation for IND filing in the United States.
The company also updated its spinal injury acute phase pipeline, noting completion of face-to-face consultations with PMDA in April 2026, agreeing on additional clinical trial designs. Additionally, the Phase III trial for vocal scar treatment completed patient enrollment, with eight facilities participating across Japan.
Kringle Pharma continues to advance its growth strategy, targeting overseas markets for spinal injury and vocal scar treatments, aiming to leverage potential global patient populations estimated at up to ¥6.6 million and 100,000 respectively.
🟢 Confidence: High AI-translated content.